

**8<sup>th</sup> World Congress on Animal Use in the Life Sciences**  
**Fairmont The Queen Elizabeth**  
**900 Rene Levesque Blvd West**  
**Montreal, QC H3B 4A5**

**NICEATM–ICCVAM Participation**

**Sunday, August 21:**

**Satellite Meeting:** Alternatives to the Pertussis Test

**Time/Location:** 12:00-5:00 p.m. – MacKenzie Room

NICEATM staff are attending the meeting

**Monday, August 22:**

**Platform Session I-18:** Report on the ICCVAM international workshop on vaccines

**Time/Location:** 12:45-2:00 p.m. – Joliette Room

Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is chairing the session

Invited Speakers include Dr. Richard McFarland, ICCVAM member, FDA/CBER, and Dr. Jodie Kulpa-Eddy, ICCVAM Chair and member, USDA

**Platform Session I-7:** Potency and safety testing of veterinary vaccines

**Time/Location:** 2:00-3:30 p.m. – Joliette Room

**Presentation:** Successful Development and Validation of an *In Vitro* Replacement Assay for *Leptospira* Potency Tests (J. Kulpa-Eddy, ICCVAM Chair and member, USDA)

**Platform Session I-8:** Safety testing for chemically-induced eye injuries: recent Three Rs advances

**Time/Location:** 2:00-3:30 p.m. – Duluth Room

**Presentation:** Development of a non-animal testing strategy for ocular hazard labeling of some specific EPA-regulated products (J. Fowle, ICCVAM member, U.S. EPA)

**Platform Session II-1:** Public accountability

**Time/Location:** 2:00-3:45 p.m. – Mackenzie Room

Dr. Suzanne Fitzpatrick, ICCVAM member, FDA/Office of the Commissioner, is a co-chair of the session

**Tuesday, August 23:**

**Poster Session I:** Safety and Efficacy Testing of Chemicals, Pharmaceuticals and Biologicals

**Time/Location:** 7:00 a.m.-3:15 p.m. – Hochelaga Room (4-6)

**Abstract I-11-575:** International Acceptance of the Nonradioactive LLNA: DA for Evaluating Allergic Contact Dermatitis Hazards

**Authors:** P Brown, J Matheson, A Jacobs, R Ward, E Margosches, E Salicru, D Allen, F Stack, W Stokes

**Abstract I-11-574:** International Acceptance of the Nonradioactive LLNA: BrdU-ELISA for Evaluating Allergic Contact Dermatitis Hazards

**Authors:** A Jacobs, J Matheson, V Malshet, J Toy, J Strickland, D Allen, T Burns, F Stack, W Stokes

**Abstract I-8-576:** Usefulness and Limitations of the Cytosensor Microphysiometer Test Method for Ocular Safety Testing

**Authors:** W Stokes, D Lowther, A Layton, J Redden, E Lipscomb, J Truax, N Johnson, D Allen

**Abstract I-1-569:** International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Human Vaccine Potency and Safety Testing

**Authors:** R McFarland, J Kulpa-Eddy, R Isbrucker, M Halder, H Kojima, D Verthelyi, M Schmitt, R Levis, N Johnson, B Jones, D Allen, W Casey, W Stokes

**Abstract I-1-570:** International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Veterinary Vaccine Potency and Safety Testing

**Authors:** J Kulpa-Eddy, R McFarland, R Isbrucker, M Halder, H Kojima, G Srinivas, K Brown, B Jones, N Johnson, D Allen, W Casey, W Stokes

**Abstract I-11-567:** Evaluation of the Murine Local Lymph Node Assay (LLNA) for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans

**Authors:** J Strickland, P Brown, J Matheson, A Jacobs, T McMahon, D Germolec, D Allen, E Salicru, T Burns, F Stack, W Stokes

**Abstract I-11-568:** Evaluation of the Murine Local Lymph Node Assay (LLNA) for Assessing the Allergic Contact Dermatitis Hazard Potential of Pesticide Formulations

**Authors:** T McMahon, D McCall, J Matheson, A Jacobs, T Burns, D Allen, W Stokes

**Abstract I-11-446:** Updated NICEATM Evaluation and International Acceptance of the Reduced Murine Local Lymph Node Assay

**Authors:** D Allen, T Burns, J Strickland, E Salicru, and W Stokes

**Platform Session I-3:** Biological and biotechnology-based therapeutics

**Time/Location:** 9:45 a.m.-12:00 p.m. – Joliette Room

**Presentation:** Informal communication with US FDA: pre-preIND approach to reduction of animal use in translational research and product development (Y. Huang, ICCVAM member, FDA/CBER)

**Session I-4:** Validation and Three Rs strategies for assessment of endocrine-active substances

**Time/Location:** 9:45 a.m.-12:00 p.m. – Duluth Room

Dr. Warren Casey, NICEATM Deputy Director and ICCVAM member, NIEHS, is a co-chair of the session

**Presentation:** Use of Tox 21 Tools From Screening and Prioritization to Risk Assessment: When, How and What? (J. Fowle, ICCVAM member, EPA)

**Presentation:** BG1Luc ER TA test method: results of an international validation study and proposed performance standards (W. Casey, NICEATM Deputy Director/ICCVAM member, NIEHS)

**Session I-13:** Toxicity testing in the 21st century

**Time/Location:** 9:45 a.m.-4:00 p.m. – St. Francois Room

**Presentation:** Tox21: Activities of the National Toxicology Program/NIEHS (R. Tice, ICCVAM Interagency Genetic Toxicity Working Group member, NIEHS)

**Wednesday, August 24:**

**Poster Session IV: Animal Welfare for Refinement and High Quality Science**

**Time/Location:** 7:00 a.m.-3:15 p.m. – Hochelaga Room (4-6)

**Abstract IV-1-292:** Eliminating Pain and Distress in Ocular Safety Testing:  
Use of Topical Anesthetics, Systemic Analgesics, and Humane Endpoints

**Authors:** W Stokes, J Merrill, D Lowther, T McMahon, J Chen, M Hashim, M Lewis, B Jones, E Lipscomb, D Allen

**Session I-5:** Nanotechnology and the Three Rs

**Time/Location:** 9:45 a.m.-12:00 p.m. – Joliette Room

**Presentation:** Three Rs and the safety assessment of nanotech drugs (A. Jacobs, ICCVAM member, FDA/CDER)

**Session II-5:** Validation of Three Rs alternative methods

**Time/Location:** 9:45 a.m.-12:00 p.m. – Mackenzie Room

Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is a co-chair of the session

**Presentation:** Validation of the 21st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward (W. Stokes, NICEATM Director, ICCVAM Executive Director)

**Session V-7:** Relevance, Reproducibility and Robustness – the other Three Rs  
Important to science and animal welfare

**Time/Location:** 9:45 a.m.-12:00 p.m. – St. Francois Room

Dr. Myrtle Davis, ICCVAM Interagency Research and Development Working Group member, NCI, is a co-chair of the session

**Session I-17:** Update on new *in vitro* models for detection and potency assessment of botulinum neurotoxin

**Time/Location:** 12:30-1:45 p.m. – Duluth Room

Dr. Warren Casey, NICEATM Deputy Director and ICCVAM member, NIEHS, is a co-chair of the session

**Session II-11:** The International cooperation on alternative test methods (ICATM)  
(updates from the National Validation Centers)

**Time/Location:** 3:15-4:15 p.m. – Duluth Room

Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is chairing the session

Dr. Stokes will also present an overview of NICEATM and ICCVAM and highlights of recent and planned ICATM contributions